#154254

Anti-CD81 [1s201]

Cat. #154254

Anti-CD81 [1s201]

Cat. #: 154254

Unit size: 100 ug

Availability: 10-12 weeks

Target: CD81 and its second extracellular domain (EC2)

Class: Monoclonal

Application: WB ; ELISA ; FACS ; IF

Reactivity: Human

Host: Mouse

£300.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Institute: University of Birmingham

Tool Details
Target Details
Applications
Handling
References

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

  • Name: Anti-CD81 [1s201]
  • Alternate name: 26 kDa cell surface protein TAPA-1,Target of the antiproliferative antibody 1, Tetraspanin-28
  • Research fields: Immunology;Microbiology
  • Class: Monoclonal
  • Conjugation: Unconjugated
  • Strain: Balb/c
  • Reactivity: Human
  • Host: Mouse
  • Application: WB ; ELISA ; FACS ; IF
  • Description: CD81 is co-opted during the life cycle of diversehuman pathogens: it is involved in hepatitis C virus (HCV) andPlasmodium sporozoite invasion of hepatocytes, and alsocontributes to the assembly and budding of human immunodeficiencyvirus and influenza A virus. Developed as a part of panel of murine monoclonalantibodies against full-length CD81 to further examine and assessed their ability to inhibit or neutralize HCV infection.
  • Immunogen: P60033, CD81_HUMAN
  • Immunogen uniprot id: P60033, CD81_HUMAN
  • Myeloma used: NS0

Target Details

  • Target: CD81 and its second extracellular domain (EC2)
  • Target background: CD81 is co-opted during the life cycle of diversehuman pathogens: it is involved in hepatitis C virus (HCV) andPlasmodium sporozoite invasion of hepatocytes, and alsocontributes to the assembly and budding of human immunodeficiencyvirus and influenza A virus. Developed as a part of panel of murine monoclonalantibodies against full-length CD81 to further examine and assessed their ability to inhibit or neutralize HCV infection.

Applications

  • Application: WB ; ELISA ; FACS ; IF

Handling

  • Format: Liquid
  • Concentration: 0.9-1.1mg/ml
  • Unit size: 100 ug
  • Storage buffer: PBS with 0.02% azide
  • Storage conditions: -15° C to -25° C
  • Shipping conditions: Shipping at 4° C

References

  • Tkachuk et al. 1975. FEBS Lett. 52(1):66-8. PMID: 1123084.